Noven, P&G partner on HSDD patches for women
MIAMI Noven Pharmaceuticals and Procter & Gamble Pharmaceuticals will develop and commercialize a line of patches to treat hypoactive sexual desire disorder in women, Noven announced Wednesday.
Under the agreement, P&G’s pharmaceutical division will have an exclusive worldwide license to the prescription testosterone patches, as well as for potential next-generation patches for treating HSDD. In return, Noven will receive royalties, and P&G will fund clinical development costs and be responsible for regulatory filings and marketing applications.
The patches use Noven’s DOT Matrix transdermal delivery technology.
HSDD is a form of sexual dysfunction that affects women, resulting in low sexual desire leading to personal distress. The Food and Drug Administration has not approved any products to treat HSDD, though P&G’s testosterone patch Intrinsa has been approved in some other countries for treating the condition.
Some fruit juices can affect efficacy of drugs, study shows
WASHINGTON Some kinds of juices may inhibit the body’s absorption of some drugs, according to a study by Canadian researchers released Tuesday.
The study showed that grapefruit, orange and apple juices can reduce the efficacy of drugs for treating cancer, heart disease, infections and organ-transplant rejections.
The researchers enlisted healthy volunteers and gave them the antihistamine fexofenadine, as well as a glass of grapefruit juice and a glass of water with a substance that makes grapefruit juice taste bitter or plain water. Subjects who drank the juice absorbed half the amount of fexofenadine that subjects who received water did.
The results of the study were presented at the American Chemical Society’s annual meeting in Philadelphia.
TriCor suit granted class-action status
NEW YORK A judge for the United States District Court for the District of Delaware has given class-action status to a lawsuit that several drug stores filed against Abbott Labs and Fournier Industrie et Sante, according to the legal news Web site Law360.
The drug stores allege that the companies filed frivolous patent-infringement lawsuits to prevent a generic version of the anti-cholesterol drug TriCor from reaching the market.
The District of Columbia and 18 states filed a similar lawsuit, alleging that Abbott’s and Fournier’s actions forced their health plans to pay higher prices for TriCor, but the judge declined to give their suits class-action status.
The chains, which include CVS Pharmacy and Louisiana Wholesale Drug, argue that the two drug companies caused them to pay unnecessarily high prices that they had to pass on to consumers.
TriCor (fenofibrate) has annual sales of more than $1 billion, according to Abbott financial data.